Lets talk data
This content: Has NOT been created, reviewed, or endorsed by Ro Has NOT been created, reviewed, or endorsed by Eli Lilly and Company (manufacturer of Zepbound) Has NOT been created, reviewed, or endorsed by Novo Nordisk A/S (manufacturer of Wegovy and Ozempic) Has NOT been created, reviewed, or endorsed by any affiliated entities Our relationship: The author is compensated when readers click links and enroll in Ro's services This compensation does NOT affect your costs (you pay the same whether using our links or going directly to Ro) The author only recommend services they believe provide value, but financial relationship exists They author is independent from the publisher
The impetus is fully on you as the consumer to utilize these services if you want to get your moneys worth
While any doctor can prescribe GLP-1 receptor agonists, many primary care providers have just recently become familiar with these drugs
View this as one component of broader lifestyle efforts
Lilly may position retatrutide as the maximum-efficacy injectable option and orforglipron as the more convenient oral option, giving doctors and patients a choice within Lilly's own portfolio
.webp)
